Moderna, Inc. (FRA:0QF)
| Market Cap | 14.49B +11.5% |
| Revenue (ttm) | 1.90B -56.1% |
| Net Income | -2.66B |
| EPS | -6.86 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 672 |
| Average Volume | 2,955 |
| Open | 37.50 |
| Previous Close | 39.44 |
| Day's Range | 36.73 - 38.09 |
| 52-Week Range | 19.26 - 46.96 |
| Beta | n/a |
| RSI | 55.92 |
| Earnings Date | Feb 13, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
PROFFITT & GOODSON INC Sells 150 Shares of Moderna Inc (MRNA)
PROFFITT & GOODSON INC Sells 150 Shares of Moderna Inc (MRNA)
Bayforest Capital Ltd Buys 6,812 Shares of Moderna Inc (MRNA)
Bayforest Capital Ltd Buys 6,812 Shares of Moderna Inc (MRNA)
Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade)
Noteworthy Friday Option Activity: V, MRNA, WDC
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Visa Inc (Symbol: V), where a total of 45,386 contracts have traded so far, representing approxi...
Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift
Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift
Moderna announces departure of medical chief
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi ...
Moderna CMO Jacqueline Miller to step down
Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.
Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Offi...
Dr. David Berman to Join Moderna as Chief Development Officer
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer...
Dr. David Berman to Join Moderna as Chief Development Officer
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer...
Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing
Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
mRNA-3927 is a strong strategic fit with Recordati's rare Metabolic portfolio Collaboration combines Moderna's expertise in mRNA technology for rare metabolic disorders with Recordati's established gl...
Moderna, Inc.: Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition t...
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Moderna will continue to lead clinical development and manufacturing for mRNA-3927 Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to ...
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to c...
This Stock Is Already Up 58% This Year. Is It a Buy?
One of Moderna's leading drug candidates is proving highly effective in clinical trials. It could help expand Moderna's lineup and boost its financial results.
Moderna (MRNA) Leads Healthcare Stocks with Impressive Gains
Moderna (MRNA) Leads Healthcare Stocks with Impressive Gains
Convergence Long/Short Equity ETF Buys 12,528 Shares of Moderna Inc (MRNA)
Convergence Long/Short Equity ETF Buys 12,528 Shares of Moderna Inc (MRNA)
Victory Growth and Tax Strategy Fund Buys 3,438 Shares of Moderna Inc (MRNA)
Victory Growth and Tax Strategy Fund Buys 3,438 Shares of Moderna Inc (MRNA)
Moderna, Inc (MRNA) Q2 2022 Earnings Call Transcript
Moderna, Inc (NASDAQ: MRNA) Q2 2022 Earnings Call dated Aug. 03, 2022 Corporate Participants: Lavina Talukdar — Senior Vice President and Head of Investor Relations Stephane Bancel — Chief Executive O...
Moderna (MRNA) Stock Pulls Back After Recent Strength
Moderna Inc (NASDAQ: MRNA) shares are down on Monday, pulling back after recent updates highlighting its latest cancer trial results. Here’s what investors need to know . Moderna stock is trending lo...
Behind the Scenes of Moderna's Latest Options Trends
Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ: MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled...
Moderna, Inc.: Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 t...
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to r...